![]() ![]() Novavax has pledged 1.35 billion doses to the world, along with the 100 million it promised the U.S. Novavax during that same period pursued deals with multiple countries and international organizations, including the Serum Institute of India and the World Health Organization, to begin distributing its vaccine across the world by the end of 2021. With that in mind, Operation Warp Speed continued to fund and support Novavax’s manufacturing over the next six months with the encouragement of top Trump officials from multiple agencies - despite clear warnings that the company had yet to solve core problems, according to five of the people who spoke to POLITICO for this story, including two former officials. ![]() citizens in controlled settings where the need for freezers could be accommodated, and then Novavax could provide an easier-to-handle vaccine to export to other countries. Operation Warp Speed officials believed that the mRNA vaccines being produced by Pfizer and Moderna could come more quickly, providing protection to U.S. “We knew that recombinant protein was going to be less fast than the other technologies because you have to make the protein in the appropriate structure. making a recombinant protein vaccine against a virus that has a lot of similarities to Covid-19 virus,” Slaoui said, referring to the company’s ongoing efforts to develop a flu vaccine. “The reason we selected Novavax is because it had accumulated significant experience in. Slaoui, the former scientific director of Covid-19 vaccine development efforts at Operation Warp Speed, confirmed his steadfast support for Novavax in an interview with POLITICO. But Slaoui, along with other Covid-19 vaccine officials, was adamant Novavax would deliver. They wanted the administration to focus instead on helping to build capacity at other companies that had more experience. manufacturing pressed the leader of their team, Moncef Slaoui, to reconsider whether to support the company. A select group of officials working with the Trump administration’s Operation Warp Speed on scaling U.S. The vaccine did not require freezer storage and thus would be easier to ship to countries in Africa, the Middle East and Asia.īut the quality and manufacturing problems Novavax faced appeared to be significant. Unlike the other vaccines commissioned by the federal government, such as new messenger RNA technology used by Pfizer and Moderna, officials believed the Novavax shot could help not only the U.S., but the farthest reaches of the world. In July 2020, the Trump administration announced it would invest $1.6 billion over time to help the company build up its manufacturing and deliver 100 million doses by the end of 2020 - more than any other investment in a Covid-19 vaccine maker up to that time. ![]()
0 Comments
Leave a Reply. |